Management of infections in the neutropenic patient.
Neutropenic patients continue to be at increased risk for developing serious infections despite substantial advances in supportive care. Epidemiologic shifts occur periodically and need to be detected early because they influence prophylactic, empiric, and specific therapy strategies. Although effective in preventing bacterial and some fungal infections, prophylaxis must be used with caution because it is associated with the emergence of resistance. The choices for empiric therapy include combination regimens and monotherapy. Specific choices depend on local factors (epidemiology, susceptibility/resistance patterns, availability). Various treatment settings (hospital-based, early discharge, outpatient) are also available, and the choice depends on the patient's risk category. Early diagnosis and treatment of many fungal and viral infections remains suboptimal. Infection control and prevention are important strategies, especially with the emergence of multidrug-resistant organisms.
Rolston
Kenneth V I
KV
Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas 77030, USA. krolston@mdanderson.org
D001424:Bacterial Infections / Q000150:complications / Q000628:therapy*; D006801:Humans; D009181:Mycoses / Q000150:complications / Q000628:therapy*; D009503:Neutropenia / Q000150:complications*; D014777:Virus Diseases / Q000150:complications / Q000628:therapy*